Figure 2From: Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemiaNilotinib is very effective in the treatment of Bcr/Abl-caused lymphoblastic leukemia in vivo. Survival of C57Bl/6J mice transplanted with 8093 lymphoma cells and treated either with nilotinib (n = 7; 75 mg/kg daily) or with vehicle (n = 8). Nilotinib-treated mice lived significantly (p < 0.01) longer than the control group.Back to article page